Publications by authors named "V Castilho"
Objective: To evaluate the relationship between premenstrual disorders (PMD) and age, we analyzed the prevalence and severity of psycho-emotional and physical symptoms in a representative sample of Brazilian women.
Methods: This observational and retrospective study analyzed data from Brazilian women aged 20-49 years from five regions of the country who reported premenstrual symptoms. Participants completed a premenstrual symptom screening questionnaire and self-reported the presence and severity of their symptoms.
Introduction: Biological monoclonal antibodies play a pivotal role in cancer treatment, with biosimilars significantly enhancing their accessibility. In Brazil's ethnically diverse setting, real-world evidence is crucial for assessing the effectiveness and applicability of these therapies in routine clinical practice.
Methods: We performed a multicentric, observational, prospective real-world study on biosimilar trastuzumab-dkst for adjuvant treatment of early HER2-positive breast cancer in Brazilian patients.
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma.
Oncol Ther
September 2024
Article Synopsis
- RTXM83, a biosimilar to rituximab, has been approved after extensive studies showed it is similar to the original drug; this includes results from a pivotal study called RTXM83-AC-01-11.
- A retrospective study in Brazil analyzed long-term outcomes for patients with diffuse large B cell lymphoma (DLBCL) who received either RTXM83 or the original rituximab alongside other chemotherapy drugs, revealing that both groups showed significant progress in treatment.
- The findings highlighted that RTXM83 had a much higher progression-free survival and overall survival rate compared to the original drug, indicating its effectiveness and safety, although further research is needed to confirm these results in
Background: Melasma is a chronic dermatosis that impacts the patient's quality of life and can present considerable challenges in terms of effective treatment.
Objective: To evaluate the effectiveness, tolerability, and safety of 5% cysteamine combined with 4% nicotinamide in female subjects with melasma.
Methods: This single-center, single-arm, prospective, open-label study evaluated patients with melasma using a combination cream of 5% cysteamine and 4% nicotinamide in a progressive regimen (60 min in the first month, 120 min in the second month, and 180 min in the third month).